In addition, liraglutide binds to albumin in plasma, and patients with NAFLD with T2DM exhibit chronic microproteinuria, further reducing liraglutide exposure [86]. The gene discussed is ALB; the disease is metabolic dysfunction-associated steatotic liver disease.